Kaiser Permanente's Genetic Database Is Boon to Medical Research
By Emily Anthes,
Bloomberg Businessweek
| 09. 25. 2014
Untitled Document
Over the past decade, Kaiser Permanente has spent more than $4 billion building the world’s largest private-sector collection of electronic health-care records. The data have become the cornerstone of a new scientific resource: a biobank that links the health records of more than 210,000 Kaiser members with samples of their DNA. The Oakland (Calif.)-based health network has teamed up with the University of California at San Francisco so scientists can use the collection to search for the genetic roots of diseases including glaucoma and prostate cancer.
Kaiser has 9.5 million enrollees in eight states and the District of Columbia, and members can see a wide variety of medical specialists without leaving the network. Every visit, lab test, prescription, and procedure is logged into a member’s electronic health record. This gives Kaiser an edge over other genomics projects, which besides collecting DNA samples must go through the expense and trouble of amassing information on subjects’ medical history. Last year biologist Craig Venter founded Human Longevity, with plans to sequence the genomes of as many as 100,000 people annually, and this summer,...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...